New Report Solves the Pharmaceutical Pipeline Problem
Market analysts estimate that most pharmaceutical firms will need to double the number of new chemical entities they develop to meet Wall Street analysts' growth expectations. Pharmaceutical-biotechnology alliances will shore up pipelines of pharmaceutical companies, reported by business intelligence firm Cutting Edge Information.
Called the pipeline problem, pharmaceutical companies are partly victims of their industry's success. Rapid growth of blockbuster products forces each major company to build a stronger pipeline of new blockbusters. Pharmaceutical-biotechnology alliances help solve the pipeline problem that plagues pharmaceutical companies. These partnerships are a new competitive ground for more blockbusters than can be developed internally.
"The first companies to build an alliance of excellence will not only increase production to meet demand, but also have a decided advantage over other pharmaceutical companies," says Cutting Edge Information CEO Jason Richardson.
Cutting Edge Information report "Building Pharmaceutical-Biotechnology Partnerships" (PH50), available at http://www.pharmabiotechalliances.com/ , shows how alliance masters such as Pfizer, Aventis, GlaxoSmithKline, AstraZeneca, Amgen, and Chiron execute their alliances with precision. One profiled company, for example, manages more than 250 R&D partnerships - an enormous commitment to its alliance effort. The company attributes much of its financial and market success to its alliance management expertise. To view the online summary of Cutting Edge Information's 145-page report, visit http://www.pharmabiotechalliances.com/PH50download.htm .
Other news from the department business & finance
